1. FDA (2019) FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. Accessed 21 Jan 2019.
https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm
.
2. EMA (2018) EU authorities take further action in ongoing review of sartans: Zheijiang Huahai placed under increased supervision; Aurobindo Pharma stopped from supplying irbesartan to the EU. Accessed 21 Jan 2019.
https://www.ema.europa.eu/en/news/eu-authorities-take-further-action-ongoing-review-sartans-zheijiang-huahai-placed-under-increased#_ftn1
3. Shanley A. After Valsartan Recalls, Regulators grapple with nitrosamine contamination in APIs. Pharma Tech 2018. Accessed 21 Jan 2019.
http://www.pharmtech.com/after-valsartan-recalls-regulators-grapple-nitrosamine-contamination-apis
4. EMA (2018b) Press release on 13th September. Update on review of valsartan medicines: risk from NDMA remains low, a related substance NDEA also being investigated. Accessed 21 Jan 2019.
https://www.ema.europa.eu/en/news/update-review-valsartan-medicines-risk-ndma-remains-low-related-substance-ndea-also-being
5. Pottegard A, Kristensen K, Ernst MT, Johansen NB, Quartorolo P, Hallas J. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. Br Med J. 2018;362:k3851.